FFA
PCRX icon

Farther Finance Advisors’s Pacira BioSciences PCRX Stock Holding History

Farther Finance Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.94K Buy
357
+112
+46% +$2.84K ﹤0.01% 4690
2026
Q2 		$6.21K Sell
245
-8,150
-97% -$193K ﹤0.01% 4679
2026
Q1 		$191K Sell
8,395
-922
-10% -$20.5K ﹤0.01% 2049
2025
Q4 		$241K Buy
9,317
+1,145
+14% +$27.2K ﹤0.01% 1798
2025
Q3 		$211K Buy
8,172
+12
+0.1% +$295 ﹤0.01% 1578
2025
Q2 		$195K Buy
8,160
+7,651
+1,503% +$193K ﹤0.01% 1403
2025
Q1 		$12.3K Buy
+509
New +$12.2K ﹤0.01% 2642
2024
Q4 		– Sell
-8
Closed -$120 – 4107
2024
Q3 		$120 Sell
8
-22
-73% -$376 ﹤0.01% 3747
2024
Q2 		$854 Buy
30
+26
+650% +$740 ﹤0.01% 3123
2024
Q1 		$117 Sell
4
-38
-90% -$1.17K ﹤0.01% 3355
2023
Q4 		$1.42K Buy
42
+37
+740% +$1.08K ﹤0.01% 2579
2023
Q3 		$153 Buy
+5
New +$180 ﹤0.01% 2504
2023
Q2 		– Sell
-15
Closed -$612 – 2545
2023
Q1 		$612 Buy
+15
New +$597 ﹤0.01% 1955

Other funds holding PCRX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Farther Finance Advisors's PCRX Position: Q3 2026 in Review

Farther Finance Advisors increased its Pacira BioSciences (PCRX) stake by 46% in Q3 2026, buying an estimated $2.84K and bringing the position to 357 shares worth $8.94K. The position accounts for ﹤0.01% of the portfolio, ranked #4690.

Farther Finance Advisors first reported a position in PCRX in Q1 2023 and has held it in 13 quarters since. The position peaked at $241K in Q4 2025. 10 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Farther Finance Advisors held 357 shares of Pacira BioSciences worth $8.94K as of Q3 2026.
  • Farther Finance Advisors bought 112 Pacira BioSciences shares in Q3 2026, an estimated $2.84K.
  • Pacira BioSciences made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #4690 holding.
  • Farther Finance Advisors first reported a position in Pacira BioSciences in Q1 2023 and has held it in 13 quarters since.
  • Farther Finance Advisors's Pacira BioSciences position peaked at $241K in Q4 2025.
  • 10 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.